Easton Pharmaceuticals Announces Neil Mellor as Senior Consulta

 
FSC / Press Release 
Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief
Operations Officer 
Toronto, Ontario CANADA, June 04, 2013 /FSC/ - Easton Pharmaceuticals Inc. (EAPH
- OTC),Easton Pharmaceuticals, a specialty pharmaceutical company that designs,
develops, and markets a premium array of topically-delivered therapeutic
healthcare products, announced today that Mr. Neil Mellor will join the company
as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of
experience in the pharmaceutical industry, both in Canada and Europe. The
majority of Mr. Mellor's background is in sales, marketing and business
development for companies such as Merck, Pharmacia (now Pfizer), and Solvay
Pharma (now Abbott Laboratories). 
Over the past 10 years, Mr. Mellor has been Associate Director of Business
Development at Solvay Pharma. In addition, Mr. Mellor served as President of the
Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and remains
an active member of the Board of the CHLA. Mr. Mellor is currently the President
of Global Health Link, a healthcare consulting company serving Canadian and US
clients. We are especially pleased to have such an accomplished professional as
Mr. Mellor on board to help with our future plans for our products, beginning
with our lead product VIORRATM," commented Mr. John Adams, of Easton
Pharmaceuticals'. "Mr. Mellor's vast experience in marketing and licensing will
help us navigate the sometimes uncertain waters of the different markets Easton
Pharmaceuticals is considering, and will help us focus on the design and
execution of key business activities which will enrich our pending
commercialization efforts." 
About Easton Pharmaceuticals Inc 
Easton Pharmaceuticals is a specialty pharmaceutical company that designs,
develops, and markets a premium array of topically-delivered therapeutic
healthcare products, focused on skin and circulatory conditions that impact a
large and expanding numbers of consumers including health issues related to male
and female sexual dysfunction, scar and stretch marks, cellulite and varicose
veins. The world market for these conditions is in excess of US$10 billion. 
The company's proprietary gel formulation is an innovative and unique
transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA,
is an over-the-counter aid to help restore and improve vaginal moisture and
elasticity which plays an important role in women's sexual desire and arousal,
FSAD (Female Sexual Arousal Disorder).  The world market for products which
treat this disorder is in excess of US$2 billion. VIORRA is a topical, daily-use
product classified by the US Food and Drug Administration (FDA) as containing
Generally Recognized as Safe ingredients. 
For more information, visit http://www.eastonpharma.com or
http://www.ashleybiomedical.com 
Contact: 
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: info@lamindustries.com
Email and Media Relations: info@ashleybiomedical.com 
To view the press release as a PDF file, please click on the following link:
http://www.usetdas.com/pr/eastonpharm06042013.pdf 
Maximum News Dissemination by FSCwire. http://www.fscwire.com 
Provider ID: 00021731
-0- Jun/04/2013 21:58 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.